ASAndreea‐Ruxandra Schmitzer

Andreea‐Ruxandra Schmitzer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andreea‐Ruxandra Schmitzer has a total of 102 co-authors. Here are the top co-authors by number of shared publications:

  • Gerardo Ferbeyre

    University of Montreal

    12 shared publications
  • Loïc Leclercq

    Univ Lille CNRS Centrale Lille Univ Artois UMR 8181 UCCS F-59000 Lille France

    10 shared publications
  • Vincent Gauchot

    Département de Chimie, Université de Montréal, CP 6128 Succursale Centre Ville, Montréal, Québec, H3C3J7 Canada

    7 shared publications
  • Jérémie Tessier

    Département de Chimie, Faculté des Arts et des Sciences, Université de Montréal, Campus MIL, 1375, Ave. Thérèse Lavoie-Roux, Montréal, Québec H2 V 0B3, Canada

    6 shared publications
  • Véronique Bourdeau

    Department of Biochemistry and Molecular Medicine, CR-CHUM and Montreal Cancer Institute, University of Montreal

    6 shared publications
  • Julien Gravel

    Department of Chemistry, University of Montréal, Faculté des Arts et des Sciences, 2900 Edouard Montpetit, CP 6128 succursalle centre ville, Montréal, QC, H3C 3J7, Canada

    5 shared publications

Latest Publications

  • Open Access

    The role of ATP synthase subunit e (ATP5I) in mediating the metabolic and antiproliferative effects of metformin in cancer cells

    by Guillaume Lefrançois, Emilie Lavallée, Marie-Camille Rowell, Véronique Bourdeau, Farzaneh Mohebali, Thierry Bertomeu, Ana Maria Duman, Maya Nikolova, Mike Tyers, Simon-Pierre Gravel, et al.

    Here, we identify the subunit e of F₁F₀-ATP synthase (ATP5I) as a target of metformin, a first-in-class antidiabetic biguanide. ATP5I maintains the stability of F₁F₀-ATP synthase dimers, which is crucial for shaping cristae morphology. We demonstrate that ATP5I interacts with a biguanide analogue in vitro, and disabling its expression by CRISPR–Cas9 in pancreatic cancer cells leads to the same phenotype as biguanide-treated cells, including mitochondrial morphology alterations, reduction of the NAD + /NADH ratio, inhibition of oxidative phosphorylation (OXPHOS), rescue of respiration by uncouplers, and a compensatory increase in glycolysis. Notably, metformin disrupts F₁F₀-ATP synthase oligomerization, leading to the accumulation of vestigial assembly intermediates in pancreatic and osteosarcoma cancer cells, a phenotype also observed upon ATP5I inactivation in pancreatic cancer cells. Moreover, ATP5I knockout (KO) cells exhibit resistance to the antiproliferative effects of biguanides, but reintroduction of ATP5I rescues the metabolic and antiproliferative effects of metformin and phenformin. Finally, a genome-wide CRISPR screening in NALM-6 lymphoma cells revealed that metformin-treated cells exhibit genetic interaction profiles similar to those observed with the F₁F₀-ATP synthase inhibitor oligomycin, but not with the complex I inhibitor rotenone. This provides unbiased support for the relevance of the newly proposed target.

  • Open Access

    The Role of ATP Synthase Subunit e (ATP5I) in Mediating the Metabolic and Antiproliferative Effects of Metformin

    by Guillaume Lefrançois, Emilie Lavallée, Marie-Camille Rowell, Véronique Bourdeau, Farzaneh Mohebali, Thierry Bertomeu, Ana Maria Duman, Maya Nikolova, Mike Tyers, Simon-Pierre Gravel, et al.

    Here we identify the subunit e of F F -ATP synthase (ATP5I) as a target of metformin, a first-in-class antidiabetic biguanide. ATP5I maintains the stability of F F -ATP synthase dimers which is crucial for shaping cristae morphology. We demonstrate that ATP5I interacts with a biguanide analogue in vitro and disabling its expression by CRISPR-Cas9 in pancreatic cancer cells leads to the same phenotype as biguanide treated cells including mitochondrial morphology alterations, reduction of the NAD+/NADH ratio, inhibition of oxidative phosphorylation (OXPHOS), rescue of respiration by uncouplers and a compensatory increase in glycolysis. Notably, metformin affects the oligomerization of the F F -ATP synthase leading to accumulation of vestigial assembly intermediates also observed upon ATP5I inactivation. Moreover, ATP5I knockout (KO) cells exhibit resistance to the antiproliferative effects of biguanides, but reintroduction of ATP5I rescues the metabolic and anti-proliferative effects of metformin and phenformin. Finally, a genome-wide CRISPR screening in NALM-6 lymphoma cells revealed that metformin-treated cells exhibit genetic interaction profiles similar to those observed with the F F -ATP synthase inhibitor oligomycin, but not with the complex I inhibitor rotenone. This provides unbiased support for the relevance of the newly proposed target.

  • Open Access

    Harnessing mitochondrial targeting: biguanide–iridium( iii ) complexes with enhanced anticancer activity in pancreatic cells

    by Sigrid Lacaille, Erica Schofield, Pierre Mas, Robert S. Horne, Barry A. Blight, Andreea R. Schmitzer

    Targeting mitochondrial function offers a compelling route for selective cancer therapy.

  • Open Access

    Mitochondria-targeting symmetric diiminoguanidines: potent and selective anticancer agents against pancreatic tumors

    by Sigrid Lacaille, Andreea R. Schmitzer

    Pancreatic cancer remains one of the deadliest malignancies of the 21st century, with a five-year survival rate below 12%.

  • Open Access

    Mitochondria-Targeting Biquaternary Ammonium Compounds: Pancreatic Anticancer Activity and Synergistic Interaction with Metformin

    by Maude Petit, Eugénie Daubas Prade, Andreea R. Schmitzer

    Challenges in pancreatic cancer treatment primarily arise from chemotherapy resistance, cancer cell metastasis, and frequent late-stage diagnoses. These issues significantly compromise the effectiveness of standard treatments and highlight the urgent need for targeted approaches. In this context, we explored the anticancer potential of bis-quaternary ammonium-based compounds (BQACs), which remains largely uncharted. This study examines the structure–activity relationship of amphiphilic bicationic compounds as anticancer agents, focusing on their selectivity against pancreatic cancer cells. Our analysis revealed a potent antiproliferative effect associated with mitochondrial accumulation and subsequent mitochondrial membrane depolarization. Furthermore, combination therapies involving BQACs and chemotherapeutic drugs were explored to enhance treatment efficacy. Consequently, we propose a novel combination of BQACs with metformin, resulting in enhanced cellular uptake of the latter. The synergistic effect of the combination enables a significantly lower effective dose of metformin when used alongside BQACs to achieve therapeutic outcomes.


  • Open Access

    Effects of Biguanide-PROTACs in Pancreatic Cancer Cells

    by Julie Vatté, Véronique Bourdeau, Gerardo Ferbeyre, Andreea R. Schmitzer

    This study focuses on the synthesis of Biguanide-PROTACs, formed by conjugating the biguanide motif with a spacer and a ligand for recognition subunits of two E3 ubiquitin ligases. Evaluation of their activity on pancreatic cancer cell (KP4) proliferation established a correlation between membrane permeability and median effective concentration. Mechanistic insights revealed that only two compounds exhibited biguanide-like AMPK activation, while only one hydrophobic compound uniquely altered mitochondrial protein levels. The prospect of developing and expanding the Biguanide-PROTAC library holds several promises, offering potential insights into biguanide mechanisms and the creation of more potent anticancer agents. This study contributes to understanding the intricate interplay between compound structure, permeability, and anticancer activity, paving the way for targeted drug development in pancreatic cancer treatment.


  • Open Access

    The Role of ATP Synthase Subunit e (ATP5I) in Mediating the Metabolic and Antiproliferative Effects of Metformin

    by Guillaume Lefrançois, Emilie Lavallée, Marie-Camille Rowell, Véronique Bourdeau, Farzaneh Mohebali, Thierry Berthomeu, Ana Maria Duman, Maya Nikolova, Mike Tyers, Simon-Pierre Gravel, et al.

    Here we identify the subunit e of F F -ATP synthase (ATP5I) as a target of metformin, a first-in-class antidiabetic biguanide. ATP5I maintains the stability of F F -ATP synthase dimers which is crucial for shaping cristae morphology. We demonstrate that ATP5I interacts with a biguanide analogue in vitro and disabling its expression by CRISPR-Cas9 in pancreatic cancer cells leads to the same phenotype as biguanide treated cells including mitochondrial morphology alterations, reduction of the NAD + /NADH ratio, inhibition of oxidative phosphorylation (OXPHOS), rescue of respiration by uncouplers and a compensatory increase in glycolysis. Notably, metformin affects the oligomerization of the F F -ATP synthase leading to accumulation of vestigial assembly intermediates also observed upon ATP5I inactivation. Moreover, ATP5I knockout (KO) cells exhibit resistance to the antiproliferative effects of biguanides, but reintroduction of ATP5I rescues the metabolic and anti-proliferative effects of metformin and phenformin. Finally, a genome-wide CRISPR screening in NALM-6 lymphoma cells revealed that metformin-treated cells exhibit genetic interaction profiles similar to those observed with the F F -ATP synthase inhibitor oligomycin, but not with the complex I inhibitor rotenone. This provides unbiased support for the relevance of the newly proposed target.

  • Open Access

    Gaining Insight into Mitochondrial Targeting: AUTAC-Biguanide as an Anticancer Agent

    by Julie Vatté, Véronique Bourdeau, Gerardo Ferbeyre, Andreea R. Schmitzer

    AUTAC-Biguanide is a hybrid compound designed to target mitochondria, inducing their degradation by mitophagy. This study unveils the potential of biguanides as cancer cell-targeting agents, emphasizing AUTAC-Biguanide’s superior antiproliferative properties compared to metformin and its selectivity for cancer cells. The mechanism behind this heightened effect includes the ability of AUTAC-Biguanide to trigger mitophagy. By providing a comprehensive analysis of these findings, this study adds valuable insights to the field of mitochondrial-targeting anticancer agents.


  • Open Access

    Gaining Insight into Mitochondrial Targeting: AUTAC-Biguanide as an Anticancer Agent

    by Julie Vatté, Véronique Bourdeau, Gerardo Ferbeyre, Andreea Schmitzer

    AUTAC-Biguanide is a hybrid compound designed to target mitochondria inducing their degradation by mitophagy. This study unveils the potential of biguanides as cancer cell-targeting agents, emphasizing AUTAC-Biguanide's superior antiproliferative properties compared to metformin and its selectivity for cancer cells. The mechanism behind this heightened effect includes the ability of AUTAC-Biguanide to triggers mitophagy. By providing a comprehensive analysis of these findings, the study adds valuable insights to the field of mitochondrial-targeting anticancer agents.

  • Open Access

    Biguanide-PROTACs: Modulating Mitochondrial Proteins in Pancreatic Cancer Cells

    by Julie Vatté, Véronique Bourdeau, Gerardo Ferbeyre, Andreea R. Schmitzer

    This study focuses on the synthesis of Biguanide-PROTACs, formed by conjugating the biguanide motif with diverse E3 enzyme ligands and spacers. Evaluation of their activity on pancreatic cancer cell (KP4) proliferation established a correlation between membrane permeability and median effective concentration. Mechanistic insights revealed that only two compounds exhibited biguanide-like AMPK activation, while only one hydrophobic compound uniquely altered mitochondrial protein levels. The prospect of developing and expanding the Biguanide-PROTAC library holds promises, offering potential insights into biguanide mechanisms and the creation of more potent anticancer agents. This study contributes to understanding the intricate interplay between compound structure, permeability, and anticancer activity, paving the way for targeted drug development in pancreatic cancer treatment.